Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Brämswig, K; Ploner, F; Martel, A; Bauernhofer, T; Hilbe, W; Kühr, T; Leitgeb, C; Mlineritsch, B; Petzer, A; Seebacher, V; Stöger, H; Girschikofsky, M; Hochreiner, G; Ressler, S; Romeder, F; Wöll, E; Brodowicz, T.
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Anticancer Drugs. 2014; 25(7):848-853
Doi: 10.1097/CAD.0000000000000108
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Ploner Ferdinand
- Stöger Herbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a named patient program in Austria. Twelve physicians from eight different hospitals provided records for the analysis of data. Among the 33 patients, the predominant histological subtype of sarcoma was leiomyosarcoma (n=18, 55%). Other subtypes were represented by only one or two cases. Fifteen patients presented with metastases at the time of diagnosis. Another 17 patients developed metastases later in the course of the disease (data on one patient are missing). Most of the 33 patients had undergone resection of the primary (n=29, 88%) and half of the patients had received radiotherapy (n=17, 52%). Chemotherapy for metastatic disease had been administered to 30 patients (91%). The majority had received two or more regimens of chemotherapy (n=25, 76%) before sorafenib treatment. The use of sorafenib resulted in a median time to treatment failure of 92 days in patients with leiomyosarcoma and 45 days in patients with other histological subtypes. One-third of the patients derived benefits from treatment: four patients were documented with partial response and six with stabilized disease. In terms of treatment-related toxicity, skin problems of various degrees and gastrointestinal disturbances were frequently reported. In this retrospective analysis of heavily pretreated patients with advanced soft tissue sarcomas, sorafenib was associated with some antitumor activity and an acceptable toxicity profile.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents - adverse effects
- Antineoplastic Agents - therapeutic use
- Female -
- Humans -
- Leiomyosarcoma - drug therapy
- Leiomyosarcoma - pathology
- Male -
- Middle Aged -
- Neoplasm Metastasis -
- Niacinamide - adverse effects
- Niacinamide - analogs & derivatives
- Niacinamide - therapeutic use
- Phenylurea Compounds - adverse effects
- Phenylurea Compounds - therapeutic use
- Retrospective Studies -
- Soft Tissue Neoplasms - drug therapy
- Soft Tissue Neoplasms - pathology
- Young Adult -
- Find related publications in this database (Keywords)
- chemotherapy
- leiomyosarcoma
- sarcoma
- sorafenib